Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced MalignanciesNeil L. Spector, Sarah Bacus|Journal of Clinical Oncology|2005Cited by 364
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer modelsWenle Xia, Neil L. Spector, Sumin Zhao et al.|Breast Cancer Research|2013Cited by 146
The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteinsBradley L. Smith, Sarah Bacus|British Journal of Cancer|2004Cited by 86